about
Nail Psoriasis: A Review of Treatment OptionsImmune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted TherapeuticsNew and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitorsTargeting of interleukin-17 in the treatment of psoriasisThe IL-23-IL-17 immune axis: from mechanisms to therapeutic testingInterleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseasesBiologic agents in nail psoriasis: efficacy data and considerations.The Role of IL-17 in the Pathogenesis and Treatment of Psoriasis.IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF).Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapyThe Changing Landscape of Alopecia Areata: The Therapeutic Paradigm.The flavonoid cyanidin blocks binding of the cytokine interleukin-17A to the IL-17RA subunit to alleviate inflammation in vivo.IL-6 as a druggable target in psoriasis: focus on pustular variants.Use of biologic agents in combination with other therapies for the treatment of psoriasisCytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside.Molecular and Cellular Profiling of Scalp Psoriasis Reveals Differences and Similarities Compared to Skin Psoriasis.Basic biology and role of interleukin-17 in immunity and inflammationThe immunogenetics of Psoriasis: A comprehensive review.Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets.Therapeutic antibodies that target inflammatory cytokines in autoimmune diseasesUpdates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting.Treating moderate to severe psoriasis - best use of biologics.Cytokine networking of innate immunity cells: a potential target of therapy.Cellular sources of IL-17 in psoriasis: a paradigm shift?Tofacitinib for the treatment of moderate-to-severe psoriasis.Interleukin-17 antagonists in the treatment of psoriasis.Interleukin-17 in systemic lupus erythematosus: A comprehensive review.The IL-23-IL-17 axis in inflammatory arthritis.Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis.Secukinumab (AIN-457) for the treatment of Psoriasis.An Update on Medical Treatment Options for Hidradenitis Suppurativa.A novel therapeutic paradigm for patients with extensive alopecia areata.Reducing Flightless I expression decreases severity of psoriasis in an imiquimod-induced murine model of psoriasiform dermatitis.Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents.Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.Brodalumab for the treatment of psoriasis.Potential route of Th17/Treg cell dynamics in targeting type 1 diabetes and rheumatoid arthritis: an autoimmune disorder perspective.Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: a meta-analysis from phase 3 randomized controlled trials.
P2860
Q26753038-FAE2EE48-8A8F-4C04-8630-34632CAB85A0Q26799532-C9548D01-6DE1-4A04-871B-621BB50F69FAQ26800937-70F815A2-51AD-405C-84E7-633425CBCB06Q27026324-CF5D0150-DCD4-4E59-A838-19746FCA8BE5Q27687800-6B84CE3F-D90A-4209-87E5-356C7AACF179Q28069350-1E6A9581-8F79-4F10-9D1E-0FD04B04A486Q30683539-E1377E02-8FF7-434F-B234-99C1DDA9A710Q33574671-FF6D238F-8BD1-4EE7-B398-F90C9323E251Q33728396-B4940B45-8AFC-41ED-8739-8F3DCB76F851Q33785074-77BE3181-93CB-4B45-924C-04792CED660EQ33890805-608F8C0B-DD54-4B03-90C5-B40ECB0C661FQ33922498-39304F82-79FD-4141-8DEE-D7DCAE667973Q34003280-30BBFE4C-10E9-4EBD-91F9-F5B185E06FD8Q34553755-3D39E06D-6BEA-4285-864A-8CB6D176AFC8Q34763844-F11E56FC-C022-4ADC-BF5A-8911800FD4D2Q35916032-A44C5C2F-664B-442C-BD3B-F5926971A732Q35932948-CADCCB41-99B5-4C9F-8850-97A68EF7772FQ36236780-FFEA1769-4FBC-41F1-8E67-0A9B240BB4A4Q36514683-99ADF6ED-144B-4D72-8A15-B3149F13705AQ36958902-0148FF18-8E38-4D90-A8AA-DE57E39A3399Q37258726-C6495F47-A646-4157-9B1E-5097697AC1A8Q38174153-ED62EA04-0951-4116-9732-4B8668603CCDQ38180799-282006D6-CACB-46E9-8FFA-FC6865EB9908Q38231403-159499BF-239B-4048-9646-1FE5F7DF4CC3Q38349779-3DFB8200-9907-4990-9969-57F8C07D3A16Q38379864-2035728E-2697-441C-97EC-B81673FE4C9BQ38430722-9345B303-1782-430F-BA35-59F6F6FE3E5FQ38439641-C66975D9-6DBB-4B6E-A2AC-C02B543ABD98Q38521383-4AE0D28C-41EF-48FC-BB2F-75B2089310EEQ38662868-9C630533-413C-40A3-A7C7-90F57B7DF16CQ38667207-41A64273-4268-4818-815C-0437F2A27415Q38831003-D907282D-DE93-47E6-ADAC-2126059C3180Q38845758-BAF1ED51-38FD-4F49-8D65-C8B650BF801BQ38856226-74EA4DAF-A225-4264-8441-B21CC44F8257Q38862695-6E28F391-0F8D-4931-997D-389BD3CA1B0FQ38935474-45A816E7-D213-45C2-B7B2-D943E6FE6066Q38961129-81BD6967-D2C4-4E85-A0D3-DA53CB8E257DQ38975719-70D952D8-90BF-4CCC-8DCA-A0E36E788131Q39027725-38154E99-5F24-4F69-9BFF-F4D21DB5DD7AQ39096719-FE1ECFE9-185F-411D-937D-7D5968A06506
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
IL-17 targeted therapies for psoriasis.
@en
type
label
IL-17 targeted therapies for psoriasis.
@en
prefLabel
IL-17 targeted therapies for psoriasis.
@en
P2860
P1476
IL-17 targeted therapies for psoriasis.
@en
P2093
Andrea Chiricozzi
James G Krueger
P2860
P304
P356
10.1517/13543784.2013.806483
P407
P577
2013-06-03T00:00:00Z